Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy

Overview

Sarcopenia is defined as a loss in skeletal muscle mass and function (strength and/or performance). There is a high prevalence in elderly and in patients with cancer. Several mechanisms are known to explain sarcopenia (inflammation, neurodegenerative process, hormonal disorders, lack of exercise, malnutrition). The consequences were analysed in several studies where sarcopenia appeared to be an independent factor of mortality, and associated with cancer-related fatigue, nosocomial infections, cardio-vascular diseases, and chemotherapy toxicities. Diagnosis is based on the measure of the muscle mass performing an abdominal computed-tomography (CT) scan, and on the measure of the muscle strength using the handgrip test with a "Jamar®" hydraulic hand dynamometer. CT scan is more invasive and less easy to reach than handgrip test. This test is used to be performing in elderly but not in cancer patients having chemotherapy. Present prospective study explored the feasibility of systematic handgrip strength testing and short-term changes in muscle strength in digestive cancer patients treated by chemotherapy.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 15, 2017

Interventions

  • Procedure: handgrip strength test
  • Drug: chemotherapy

Arms, Groups and Cohorts

  • Experimental: patient undergoing to chemotherapy during 6 months

Clinical Trial Outcome Measures

Primary Measures

  • number of patients having at least one handgrip strength test among all hospitalized cancer patients undergoing chemotherapy
    • Time Frame: 6 months
  • Evaluation of handgrip test by patients
    • Time Frame: after 3 months
  • Evaluation of handgrip test by staff (nurses, interns, students)
    • Time Frame: 6 months
  • number of handgrip strength test measures per patient, number of handgrip test measures compared to the number of day hospitalisations, number of patients who had all of the measures, between 50 and 100% of measures, less than 50% of measures
    • Time Frame: 6 months

Secondary Measures

  • to study the association between hand grip strength test and tolerance to chemotherapy
    • Time Frame: 6 months
  • to follow the short term evolution of hand grip strength test during 6 months in patients undergoing chemotherapy
    • Time Frame: 6 months
  • to study the association between the evolution of hand grip strength test and the evolution of nutritional indices (anthropometric and biologic)
    • Time Frame: 6 months

Participating in This Clinical Trial

Inclusion Criteria

  • patients with digestive cancer having a chemotherapy and/or biotherapy in the department of Reims – > 18 years old – after patient agreement – linked to social security system Exclusion Criteria:

  • legal guardianship – < 18 years old – neuro-muscular issue

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • CHU de Reims
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.